Aflac Voices — Buffy Swinehart: Giving Back Is Good for Well-Being
When I look back over my 23 years in the philanthropic world, the highlights reel consists of a lot of inspiring moments — delivering smiles with My Special Aflac Duck® for children with cancer and sickle cell disease, creating special moments for children and families facing those same conditions, and tallying the ever-growing donations made to the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta (which is now nearly $190 million to date).
I am a firm believer in the saying 'there is strength in numbers.' It has been a privilege to share in moments when our employees get involved, whether it's with the causes mentioned above or other activities throughout their own communities. There is a sense of passion and joy on display, not just in their volunteer work but in their day-to-day work, as well.
It's something that I've known and felt for years, and with the Aflac WorkForces Report, we have the data to back it up: Corporate social responsibility (CSR) boosts well-being. In fact, a staggering 91% of employees who participate in their employers' CSR initiatives say it has a positive impact.
At Aflac, this comes as no surprise — we are rooted in a culture of caring for others. We make a point to share our philanthropic activities regularly and invite employees to give back to causes that align with their passions. But for many organizations, the culture is different. According to the same report, 1 in 4 survey respondents who do not participate in CSR activities said they don't know about their employers' CSR efforts. Other reasons cited for not participating include that they either don't see the impact of CSR activities or don't feel encouraged by management to participate, emphasizing the importance of both companies and leadership communicating and encouraging participation in CSR efforts.
There lies a simple yet big opportunity: Talk about your company's goodness more.
A few tips to make the most of your philanthropy program:
Whatever role you play in your organization, I encourage you to gather a team together and take a few hours to volunteer with an organization or help your community. Most importantly, you'll be giving time and resources to those in need, and you'll likely build a stronger bond and greater respect — both for your colleagues and for your community.
# # #
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare is now the exclusive pharmacy partner for IWILFIN™, a groundbreaking therapy used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB). Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. Share All patients will continue to receive IWILFIN™ as prescribed, now with an enhanced IWILFIN Cares experience powered by personalized care and digital engagement tools. This new era of clinical support delivers a seamless, elevated experience driven by advanced technology and a compassionate team of experts dedicated exclusively to high-risk neuroblastoma care. 'We're excited to launch our partnership with Curant Rare, a decision driven by one clear priority—our patients,' said Michelle Stantz, Executive Director of Market Access at US WorldMeds. 'Transitioning the IWILFIN Cares program to a new Specialty Pharmacy Partner was a tough decision and we needed to find the right partner. Curant Rare is that partner. Together, we are committed to putting patients first— ensuring our patients receive the support and treatment they need, now and into the future.' Patients and caregivers can look forward to a more connected and supportive IWILFIN Cares experience through the introduction of several features. Enhanced digital engagement will offer curated educational content to help families better understand and navigate the treatment journey. Shipment visibility tools, including real-time courier tracking and proactive shipment reminders, ensure that patients always know when to expect their medication. With smart routing and bi-directional texting, patients and caregivers can connect directly to their dedicated Patient Care Coordinator every time, helping patients and caregivers build strong, ongoing relationships with their support team and develop longitudinal care throughout their treatment journey. Additionally, insurance and financial support services will be fully managed by the Curant Rare team, including coordination of approvals, prior authorizations, and exploration of financial assistance options to help minimize out-of-pocket costs. This partnership underscores Curant Rare's commitment and dedication to delivering exceptional, patient-centered care for families navigating high-risk neuroblastoma. By ensuring uninterrupted access to therapy, Curant Rare empowers patients and caregivers with unparalleled support, seamless communication, and a transformative, modern care experience. For more information on the IWILFIN Cares program, patients and families are encouraged to contact Curant Rare at 877-IWILFIN (877-494-5346) or visit About Curant Rare Curant Rare, a specialized Curant Health Business Unit, provides bespoke specialty pharmacy and Real-World Evidence solutions to provide best-in-class rare disease patient and provider journeys. Curant Rare's personalized approach to patient care focuses on rare and ultra-rare patient populations to improve outcomes in measurable and meaningful ways. Curant Rare provides comprehensive high-quality care while placing the patient's physical and psychosocial well-being as a priority through their validated Medication Care Management® services. With over 25 years of experience, Curant Rare brings a proven track record in best-in-class patient adherence and Quality of Life. About US WorldMeds US WorldMeds is a privately held specialty pharmaceutical company that develops, licenses, and markets unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. More information on US WorldMeds can be found at IWILFIN is a registered trademark of USWM, LLC. US WORLDMEDS is a registered trademark of USWM, LLC. USWMIWI-00043 12/2023 IMPORTANT SAFETY INFORMATION Indication IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Warnings and Precautions IWILFIN can cause myelosuppression and hepatotoxicity. CBC and liver function tests should be performed before starting treatment and as clinically indicated for the duration of treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity. IWILFIN can cause hearing loss. Monitor hearing before and during treatment with IWILFIN. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity. IWILFIN can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective contraception. Adverse Reactions The most common (≥5%) adverse reactions are hearing loss, otitis media, pyrexia, pneumonia, and diarrhea. The most common (≥2%) Grade 3 or 4 laboratory abnormalities are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin.
Business Wire
5 hours ago
- Business Wire
Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with Novartis. Through this strategic collaboration, Atropos Health will build, train and evaluate multiple models to help streamline identification of people with a rare disease who have not yet been diagnosed, ultimately reducing time from symptom reporting to testing, diagnosis and treatment. The collaboration will specifically focus on paroxysmal nocturnal hemoglobinuria (PNH), a rare, serious blood disorder. Adults with PNH often experience lengthy diagnostic delays—many wait over a year, and some more than five—because the disease is rare and presents varied symptoms affecting multiple organs. 1,2 As a part of this collaboration, Atropos Health has developed an initial AI model for finding potential patients with PNH who have not yet been diagnosed, aimed to save critical time for both patients and providers by helping health systems accelerate appropriate diagnosis. The AI model is now available for integration into health systems. 'Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. 'The accuracy of the models reduces the guesswork and patients who are able to get testing sooner provides a potentially life-changing experience. For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction.' The goal of the strategic collaboration is to build and publish patient-finding models aimed at reducing time from initial symptoms to testing, diagnosis and treatment. The models created by Atropos Health in connection with this collaboration will be implemented across health system members of the Atropos Evidence Network and be seamlessly integrated at the point of care to improve the provider and patient experience. Through this collaboration, Atropos Health will build models trained on real-world data (RWD) from the Atropos Evidence™ Network, which includes GENEVA OS ®. 'At Novartis, we are committed to delivering meaningful impact for patients. Accelerating diagnosis and treatment through AI and machine learning has the power to significantly improve patient outcomes by enabling faster access to appropriate care,' said Rodney Gillespie, Head of Oncology, Novartis US. 'Our collaboration with Atropos Health to develop an AI model for identifying PNH embodies this commitment as it advances precision health, potentially enabling earlier diagnosis and timely care, reducing delays that can greatly affect patients' lives.' About paroxysmal nocturnal hemoglobinuria (PNH) PNH is a rare, chronic and serious complement-mediated blood disorder 3. People with PNH have an acquired mutation in some of their hematopoietic stem cells (which are located in the bone marrow and can grow and develop into red blood cells [RBCs], white blood cells and platelets) that causes them to produce RBCs that are susceptible to premature destruction by the complement system. 4 It is estimated that approximately 10-20 people per million worldwide live with PNH. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. 5,6 Today's announcement follows Atropos Health's AI model training capabilities released earlier this year. Atropos Evidence Network membership benefits include the ability to leverage the network to deliver AI models to clinicians. Atropos Health is collaborating with Arcadia to help leading healthcare organizations deliver the latest care protocols and advanced precision medicine at scale. The partnership enables healthcare providers to accelerate clinical decision-making with actionable, AI-powered insights at the point of care using the combination of real-world evidence (RWE) and longitudinal patient records to improve outcomes and drive high-value, low-cost care. Healthcare organizations are also engaged with Atropos Health on leveraging AI for precision medicine, and building MOTOR, CLMBR and Foundation models on the Atropos Evidence Network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. _________________________ 1 Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8. PMID: 33356781; PMCID: PMC10408416 2 Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematol Rep. 2018 Mar 29;10(1):7523. doi: 10.4081/hr.2018.7523. PMID: 29721255; PMCID: PMC5907647. 3 Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. 4 Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. 5 Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. 6 Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3-11. Expand
